| P50 | author | Andreas C Themistocleous | Q57020715 |
| | David L Bennett | Q59564348 |
| | Solomon Tesfaye | Q42699005 |
| P2093 | author name string | Andrew S C Rice | |
| | James J Cox | |
| | Stephen J Tucker | |
| | Iulia Blesneac | |
| | Carl Fratter | |
| | Juan D Ramirez | |
| | Linus J Conrad | |
| | Pallai R Shillo | |
| P2860 | cites work | Multiple arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A | Q24337302 |
| | T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension | Q24603117 |
| | Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 |
| | Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia | Q24675844 |
| | Crystal Structure of the Ternary Complex of a NaV C-Terminal Domain, a Fibroblast Growth Factor Homologous Factor, and Calmodulin | Q27681192 |
| | Comparative protein structure modeling of genes and genomes | Q27860712 |
| | Comparative protein modelling by satisfaction of spatial restraints | Q27860866 |
| | T-Coffee: A novel method for fast and accurate multiple sequence alignment | Q27860999 |
| | Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis | Q28085455 |
| | SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes | Q28118877 |
| | Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology | Q28278604 |
| | An SCN9A channelopathy causes congenital inability to experience pain | Q28278844 |
| | European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the [...] | Q28288249 |
| | Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons | Q43323322 |
| | Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). | Q44562517 |
| | Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome | Q44643471 |
| | Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy | Q45771999 |
| | Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics | Q46083277 |
| | NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. | Q46301976 |
| | 3DCoffee: combining protein sequences and structures within multiple sequence alignments | Q47333724 |
| | Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution | Q48255148 |
| | Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point? | Q48257623 |
| | Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. | Q48430447 |
| | Structure of the Nav1.4-β1 Complex from Electric Eel. | Q50875530 |
| | Quantitative sensory testing: a comprehensive protocol for clinical trials. | Q51832048 |
| | Validation of the Brief Pain Inventory for chronic nonmalignant pain. | Q51942165 |
| | Pain thresholds, supra-threshold pain and lidocaine sensitivity in patients with erythromelalgia, including the I848Tmutation in NaV 1.7. | Q53504369 |
| | Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values | Q57386944 |
| | Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy | Q78432025 |
| | Development and validation of the Neuropathic Pain Symptom Inventory | Q79798143 |
| | Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents | Q82656688 |
| | Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability | Q84008522 |
| | Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral ne | Q85170003 |
| | Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia | Q89133687 |
| | Statistical potential for assessment and prediction of protein structures | Q29615145 |
| | Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy | Q30048469 |
| | New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain | Q30235132 |
| | Comparative Protein Structure Modeling Using MODELLER | Q30366550 |
| | A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome | Q33504524 |
| | Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data | Q33725009 |
| | Pain perception is altered by a nucleotide polymorphism in SCN9A | Q33739909 |
| | Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments | Q34153575 |
| | Neuropathic pain: an updated grading system for research and clinical practice | Q34523633 |
| | Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. | Q34743192 |
| | Expresso: automatic incorporation of structural information in multiple sequence alignments using 3D-Coffee | Q34974325 |
| | Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study | Q34994547 |
| | Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. | Q35225448 |
| | Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation | Q36019152 |
| | Ca2+ toxicity due to reverse Na+/Ca2+ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation | Q36032974 |
| | Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications | Q36580250 |
| | The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy | Q36807236 |
| | Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia | Q36832246 |
| | SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity | Q36973391 |
| | Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. | Q37055488 |
| | A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration of small-diameter axons associated with intracellular Ca2+ dysregulation and decrease in ATP levels. | Q37403813 |
| | Risk factors for neuropathic pain in diabetes mellitus. | Q37713257 |
| | Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach | Q38053268 |
| | The Na(V)1.7 sodium channel: from molecule to man. | Q38066723 |
| | Painful and painless channelopathies. | Q38210568 |
| | Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. | Q38260278 |
| | 3DCoffee@igs: a web server for combining sequences and structures into a multiple sequence alignment | Q38421333 |
| | Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. | Q38755536 |
| | p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder. | Q38950260 |
| | The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study | Q39202304 |
| | Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation | Q39965463 |
| | Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles | Q42327992 |
| | Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. | Q42686664 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 469-480 | |
| P577 | publication date | 2018-03-01 | |
| P1433 | published in | Pain | Q2317902 |
| P1476 | title | Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy | |
| P478 | volume | 159 | |